Mono-, Di-, and triaryl substituted tetrahydropyrans as cyclooxygenase-2 and tumor growth inhibitors. Synthesis and biological evaluation

Journal of Medicinal Chemistry

Volumn 53, Issue 9, 2010, Pages 3707-3717

  Singh, Palwinder ^a   Bhardwaj, Atul ^a  

^a GURU NANAK DEV UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 ((ETHYLTHIO)METHYL) 6 (4 FLUOROPHENYL)TETRAHYDRO 4 PHENYL 2H PYRAN 4 OL; 2 ((ETHYLTHIO)METHYL)TETRAHYDRO 4,6 DIPHENYL 2H PYRAN 4 OL; 2 ((ETHYLTHIO)METHYL)TETRAHYDRO 6 METHYL 4 PHENYL 2H PYRAN 4 OL; 2 (4 BROMOPHENYL) 6 ((ETHYLTHIO)METHYL)TETRAHYDRO 3,4 DIPHENYL 2H PYRAN 4 OL; 2 (4 BROMOPHENYL) 6 ((ETHYLTHIO)METHYL)TETRAHYDRO 4 PHENYL 2H PYRAN 4 OL; 2 (4 BROMOPHENYL)TETRAHYDRO 3,4 DIPHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; 2 (4 BROMOPHENYL)TETRAHYDRO 4 PHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; 2 (4 CHLOROPHENYL) 6 ((ETHYLTHIO)METHYL)TETRAHYDRO 3,4 DIPHENYL 2H PYRAN 4 OL; 2 (4 CHLOROPHENYL) 6 ((ETHYLTHIO)METHYL)TETRAHYDRO 4 PHENYL 2H PYRAN 4 OL; 2 (4 CHLOROPHENYL)TETRAHYDRO 3,4 DIPHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; 2 (4 CHLOROPHENYL)TETRAHYDRO 4 PHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; 2 (4 FLUOROPHENYL)TETRAHYDRO 3,4 DIPHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; 2 (4 FLUOROPHENYL)TETRAHYDRO 4 PHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; 6 ((ETHYLTHIO)METHYL) 2 (4 FLUOROPHENYL)TETRAHYDRO 3,4 DIPHENYL 2H PYRAN 4 OL; 6 ((ETHYLTHIO)METHYL)TETRAHYDRO 2,3,4 TRIPHENYL 2H PYRAN 4 OL; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; KETONE DERIVATIVE; TETRAHYDRO 2 METHYL 4 PHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; TETRAHYDRO 2,3,4 TRIPHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; TETRAHYDRO 2,4 DIPHENYL 6 (THIOCYANATOMETHYL) 2H PYRAN 4 OL; TETRAHYDROPYRAN DERIVATIVE; UNCLASSIFIED DRUG;

ALLYLATION; ARTICLE; CANCER INHIBITION; CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; CYCLIZATION; DRUG ACTIVITY; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULE; PROTON NUCLEAR MAGNETIC RESONANCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYCLOOXYGENASE 2 INHIBITORS; GROWTH INHIBITORS; HUMANS; HYDROCARBONS, AROMATIC; PROTEIN BINDING; PYRANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77952073267     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1001327     Document Type: Article

References (67)

1. McGettigan, P.; Henry, D. Current problems with non-specific COX inhibitors Curr. Pharm. Des. 2006, 6, 1693-1724 and references therein
2. Marx, V. Chem. Eng. News 2004, 82, 8
3. Dogne, J.-M.; Supuran, C. T.; Pratico, D. Adverse cardiovascular effects of the coxibs J. Med. Chem. 2005, 48, 2251-2257
4. Jeffrey, S. B.; Lee, S. S. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance Arthritis Res. Ther. 2005, 7, S14-S22
5. Grosser, T.; Fries, S.; FitzGerald., G. A. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities J. Clin. Invest. 2006, 116, 4-15
6. Harris, R. C.; Breyer, M. D. Update on cyclooxygenase-2 inhibitors Clin. J. Am. Soc. Nephrol. 2006, 1, 236-245
7. Longford, R. M.; Mehta, V. Selective cyclooxygenase inhibition: its role in pain and anaesthesia Biomed. Pharmacother. 2006, 60, 323-328
8. Marnett, L. J. The Coxib experience. A look in the rearview mirror Annu. Rev. Pharmacol. Toxicol. 2009, 49, 265-290
9. Singh, P.; Mittal, A. Current status of COX-2 inhibitors Mini-Rev. Med. Chem. 2008, 8, 73-90 and references therein
10. Da Cunha, E. F. F.; Ramlho, T. C.; Josa, D.; Caetano, M. S.; De Souza, T. C. S. Targeting inhibition of COX-2: a review of patents, 2002-2006 Recent Pat. Inflammation Allergy Drug Discovery 2007, 1, 108-123
11. Vane, J. R. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs Nat. New Biol. 1971, 231, 232-235
12. Smith, W. L.; Garavito, R. M.; DeWitt, D. L. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2 J. Biol. Chem. 1996, 271, 33157-33160
13. Marnett, L. J.; Rowlinson, S. W.; GoodwD. C.; Kalgutkar, A. S.; Lanzo, C. A. Arachidonic acid oxygenation by COX-1 and COX-2 J. Biol. Chem. 1999, 274, 22903-22906
14. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D.; Miyashiro, J. M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents Nature 1996, 384, 644-648
15. Chandersekharan, N. V.; Dai, H.; Roos, K. L. T.; Evanson, N. K.; Tomsik, J.; Elton, T. S.; Simmons, D. L. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 13926-13931
16. Kis, B.; Snipes, J. A.; Busija, D. W. Acetaminophen and the cyclooxygenase-3 puzzle. Sorting out facts, fictions and uncertainties J. Pharmacol. Exp. Ther. 2005, 315, 1-7
17. Meric, J.-B.; Rottey, S.; Olaussen, K.; Soria, J.-C.; Khayat, D.; Rixe, O.; Spano, J.-P. Cyclooxygenase-2 as target of anticancer drug development Crit. Rev. Oncol. Hematol. 2006, 59, 51-64 (Pubitemid 43903278)
18. Liu, C. H.; Chang, S.-H.; Narko, K.; Trifan, O. C.; Wu, M.-T.; Smith, E.; Haudenschild, C.; Lane, T. F.; Hla, T. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice J. Biol. Chem. 2001, 276, 18563-18569
19. Subbaramaiah, K.; Dannenberg, A. J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment Trends Pharmacol. Sci. 2003, 24, 96-102
20. Brown, J. R.; DuBois, R. N. COX-2: a molecular target for colorectal cancer prevention J. Clin. Oncol. 2005, 23, 2840-2855
21. Dempke, W.; Rie, C.; Grothey, A.; Schmoll, H.-J. Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 2001, 127, 411-417
22. SorokA. Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phenotype Curr. Pharm. Des. 2004, 10, 647-657
23. Fantappie, O.; Masini, E.; Sardi, L.; Raimondi, L.; Bani, D.; Solazzo, M.; Vannacci, A.; Mazzanti, R. The MDR phenotype is associated with the expression of COX-2 and iNOS in a human heptacellular carcinama cell line Hepatology 2002, 35, 843-852
24. Thun, M. J.; Henkey, S. J.; Patrono, C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic and clinical issues J. Natl. Cancer Inst. 2001, 94, 252-266
25. Pommery, N.; Taverne, T.; Telliez, A.; Goossens, L.; Charlier, C.; Pommery, J.; Goossens, J.-F.; HoussR.; Durant, F.; Henichart, J.-P. New COX-2/5-LOX inhibitors: apoptosis-inducing agents potentially useful in prostate cancer chemotherapy J. Med. Chem. 2004, 47, 6195-6206
26. Peek, R. M., Jr. Prevention of colorectal cancer through the use of COX-2 selective inhibitors Cancer Chemother. Pharmacol. 2004, 54 (S1) S50-S56
27. Lu, X.; Xie, W.; Reed, D.; Bradshaw, W. S.; Simmons, D. L. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 7961-7965
28. Higuchi, T.; Iwama, T.; Yoshinaga, K.; Toyooka, M.; Taketo, M. M.; Sugihara, K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients Clin. Cancer Res. 2003, 9, 4756-4760 and references therein
29. Blobaum, A. L.; Marnett, L. J. Structural and functional basis of cyclooxygenase inhibition J. Med. Chem. 2007, 50, 1425-1441 and references therein
30. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 Nat. Struct. Biol. 1996, 3, 927-933
31. Singh, P.; Bhardwaj, A.; Kaur, S.; Kumar, S. Design, synthesis and evaluation of tetrahydropyran based COX-1/2 inhbitors Eur. J. Med. Chen. 2009, 44, 1278-1287
32. Singh, P.; Mittal, A.; Kaur, S.; Kumar, S. 5-Substituted-2, 3-diphenyltetrahydrofurans: a new class of moderatelyselective COX-2 inhibitors Bioorg. Med. Chem. 2006, 14, 7910-7916
33. Singh, P.; Mittal, A.; Kaur, S.; Holzer, W.; Kumar, S. 2,3-Diaryl-5-ethylsulfanylmethyltetrahydrofurans as a new class of COX-2 inhibitors and cytotoxic agents Org. Biomol. Chem. 2008, 6, 2706-2712
34. Rao, P. N. P.; UddM. J.; Knaus, E. E. Design, synthesis and Structure-activity relationship studies of 3,4,5-triphenylpyran-2-ones as selective cyclooxygenase-2 inhibitors J. Med. Chem. 2004, 47, 3972-3990
35. Larrosa, I.; Romea, P.; Urpi, F. Synthesis of six-membered oxygenated heterocycles through carbon-oxygen bond forming reactions Tetrahedron 2008, 64, 2683-2723
36. Colobert, F. R.; Mazery, D.; Solladie, G.; Carreno, M. C. First enantioselective total synthesis of (-)-centrolobine Org. Lett. 2002, 4, 1723-1725 and references therein
37. 38 fragment, of phorboxazoles Org. Lett. 2004, 6, 4335-4338
38. Carrillo, R.; Leon, L. G.; MartT.; MartV. S.; Padron, J. M. Synthesis and antiproliferative activity of (2 R,3 R)-disubstituted tetrahydropyrans Bioorg. Med. Chem. Lett. 2006, 16, 6135-6138 and references therein
39. Roth, S.; Stark, C. B. W. Efficient oxidative cyclization of 1,6-dienes: a highly diastereoselective entry to substituted tetrahydropyrans Angew. Chem., Int. Ed. 2006, 45, 6218-6221
40. Blanc, A.; Toste, F. D. Enantioselective synthesis of cyclic ethers through a vanadium-catalyzed resolution/oxidative cyclization Angew. Chem., Int. Ed. 2006, 45, 2096-2099
41. Carreno, M. C.; Mazery, R. D.; Urbano, A.; Colobert, F.; Solladie, G. Reductive cyclizations of hydroxysulfinyl ketones: enantioselective access to tetrahydropyrans and tetrahydrofuran derivatives J. Org. Chem. 2003, 68, 7779-7787
42. Chang, M.-Y.; LC.-Y.; Hung, C.-Y. Synthesis of cis -3,4-diarylpiperidines and cis -3,4-diaryltetrahydropyrans Tetrahedron 2007, 63, 3312-3320
43. Estevez, J. C.; Fairbanks, A. J.; Fleet, G. W. J. Synthesis of tetrahydropyrans from sugar lactones Tetrahedron 1998, 54, 13591-13620
44. Lu, L.-Q.; Xing, X.-N.; Wang, X.-F.; Ming, Z.-H.; Wang, H.-M.; Xiao, W.-J. Highly chemo- and diastereoselective synthesis of substituted tetrahydropyran-4-ones via organocatalytic oxa-Diels-Alder reactions of acyclic α,β-unsaturated ketones with aldehydes Tetrahedron Lett. 2008, 49, 1631-1635
45. Tietze, L. F.; Kettschau, G.; Gewert, J. A.; Schuffenhauer, A. Hetero-Diels-Alder reactions of 1-oxa-1,3-butadienes Curr. Org. Chem. 1998, 2, 19-62
46. Schmidt, R. R. Hetero-Diels-Alder reaction in highly functionalized natural product synthesis Acc. Chem. Res. 1986, 19, 250-259
47. Gillingham, D. G.; Kataoka, O.; Garber, S. B.; Hoveyda, A. H. Efficient enanatioslective synthesis of functionalized tetrahydropyrans by Ru-catalyzed asymmetric ring-opening metathesis/cross-metathesis (AROM/CM) J. Am. Chem. Soc. 2004, 126, 12288-12290 and references therein
48. Yang, X.-F.; Mague, J. T.; Li, C.-J. Diastereoslective synthesis of polysubstituted tetrahydropyrans and thiacyclohexanes via indium trichloride mediated cyclizations J. Org. Chem. 2001, 66, 739-747
49. Kataoka, K.; Ode, Y.; Matsumoto, M.; Nokami, J. Convenient synthesis of highly optically active 2,3,4,6-tetrasubstituted tetrahydropyrans via Prins cyclization reaction (PCR) of optically active homoallylic alcohols with aldehydes Tetrahedron 2006, 62, 2471-2483
50. Reddy, U. C.; Bondalapati, S.; Saikia, A. K. Stereoslective one-pot, three-component synthesis of 4-aryltetrahydropyran via Prins-Friedel-Craft reaction J. Org. Chem. 2009, 74, 2605-2608
51. Chan, K.-P.; Seow, A.-H.; Loh, T.-P. Stereochemical Prins cyclization: electronic versus steric effects on the synthesis of 2,4,6-trisubstituted tetrahydropyran rings Tetrahedron Lett. 2007, 48, 37-41
52. Yadav, J. S.; Reddy, B. V. S.; Kumar, G. G. K. S. N.; Swamy, T. Iodine as a versatile reagent for the Prins-cyclization: an expeditious synthesis of 4-iodotetrahydropyran derivatives Tetrahedron Lett. 2007, 48, 2205-2208
53. Jasti, R.; Vitale, J.; Rychnovsky, S. D. Axial selective Prins cyclizations by solvolysis of α-bromo ethers J. Am. Chem. Soc. 2004, 126, 9904-9905
54. Denmark, S. E.; Stavenger, R. A.; Wong, K.-T. Lewis base-catalyzed, asymmetric aldol additions of methyl ketone enolates J. Org. Chem. 1998, 63, 918-919
55. Mukaiyama, T.; Banno, K.; Narasaka, K. New cross-aldol reactions. Reactions of silyl enol ethers with carbonyl compounds activated by titanium tetrachloride J. Am. Chem. Soc. 1974, 27, 7503-7509
56. Mukaiyama, T.; Narasaka, K.; Banno, K. New aldol type reactions Chem. Lett. 1973, 1011-1014
57. Kim, J. G.; Waltz, K. M.; Garcia, I. F.; Kwiatkowski, D.; Walsh, P. J. Catalytic asymmetric allylation of ketones and a tandem asymmetric allylation/diastereoselective epoxidation of cyclic ketones J. Am. Chem. Soc. 2004, 126, 12580-12585
58. Marshall, J. A. Chiral allylic and allenic stannanes as reagents for asymmetric synthesis Chem. Rev. 1996, 96, 31-48
59. Loh, T.-P.; YZ.; Song, H.-Y.; Tan, K.-L. Indium mediated allylation of carbonyl compounds with an allylic bromide in aqueous media: Anomalous syn -diastereoselectivity regardless of allylic bromide geometry Tetrahedron Lett. 2003, 44, 911-914
60. β with heteroatomic functional groups. Analysis of the modulation in diastereoselectivity attainable in aqueous, organic and mixed solvent systems J. Am. Chem. Soc. 1996, 118, 1931-1937
61. Li, C. J.; Chan, T.-H. Organic synthesis using indium mediated and catalyzed reactions in aqueous media Tetrahedron 1999, 55, 11149-11176
62. Togo, H.; Lida, S. Synthetic use of molecular iodine for organic synthesis Synlett 2006, 2159-2175
63. COX-inhibitor screening assay kits (cat. no. 560101) were obtained from Cayman Chemical, and the standard protocol, as supplied along with the kit, was followed for evaluations of COX-1/2 inhibitory activities.
64. Singh, P.; Mittal, A.; Kumar, S. 2,3,5-Substituted tetrahydrofurans as cancer chemopreventives. Part 1: Synthesis and anti-cancer activities of 5-hydroxymethyl-2,3-diary-tetrahydro-furan-3-ols Bioorg. Med. Chem. 2007, 15, 3990-3996
65. Wallace, J. M. Nutritional and botanical modulation of the inflammatory cascade - eicosanoids, cyclooxygenases and lipoxygenases - as an adjunct in cancer therapy Integr. Cancer Ther. 2002, 1, 7-37
66. Mark, A. ArgusLab, version 4.0.1; Thompson Planaria Software LLC: Seattle, WA; http://www.arguslab.com.
67. SYBYL Molecular Modeling System, version 7.1; Tripos Inc. (St. Louis, MO 63144-2913).